A comparison between TXB_2,GMP-140 and PAI in patients with cerebrovascular disease
- VernacularTitle:脑血管病患者血栓素B_2、血小板颗粒膜蛋白?-140和6酮前列腺素1?的测定及其意义
- Author:
Guiyou LUO
;
Huakui YUE
;
Yun MA
- Publication Type:Journal Article
- Keywords:
Intracranial arteriosclerosis;
Intracranial thrombosis;
P-selectin;
6-Ketoprostaglandin F1 alpha;
Plasminogen inactivators;
Receptors, thromboxane A2 , prostaglandin H2;
Plasmin;
Endothelial cells
- From:
Chinese Journal of Primary Medicine and Pharmacy
2005;0(11):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the effects and clinical significance of plasma thromboxane B2(TXB2), platelet alpha granule membrance protein-140(GMP-140), 6-Keto-PGF1?(6-K-PGF1?), endothelins(ET), tissue type plasminogen activator(tPA) and plaminogen activator inhibitor-1(PAI-1) in patients with cerebral arteriosclerisis and cerebral thrombosis. Methods Plasma TXB2 ,GMP-140,6-K-PGFla and ET levels were determined by ra-dioimmuno-assay. Plasma tPA and PA1 were determined by the chromogenic peptide substrate method in controls and in patients with cerebral arteriosclerisis and cerebral thrombosis. Results The levels of plasma TXB2 and GMP-140 were significantly higher in patients with cerebral arteriosclerisis and cerebral thrombosis than in the control group(P0.05) .The levels of tPA and tPA/PAI were significantly lower in patients with cerebral arteriosclerisis and cerebral thrombosis than in controls. Although the PAI level increased in patients with cerebral arteriosclerisis and cerebral thrombosis,no difference was found in statistics. Conclusions Activation of platelets, injury of endothelial cell and decreased activity of fibrinolysis in patients with cerebrovascular disease may be involved in the development of these diseases. Appropriate treatment should be adopted on the above abnormality.
